CANO

Cano Health Inc - Ordinary Shares - Class A

Healthcare, SPAC


Presented:02/12/2021
Price:$16.01
Cap:$1.38B
Current Price:$2.30
Cap:$0.01B

Presented

Date02/12/2021
Price$16.01
Market Cap$1.38B
Ent Value$0.90B
P/E RatioN/A
Book Value$7.74
Div Yield0%
Shares O/S86.25M
Ave Daily Vol1,681,163
Short IntN/A

Current

Price$2.30
Market Cap$0.01B
Cano Health, LLC owns and operates health care centers and pharmacies. It provides medical, dental, urgent care, an in-house laboratory, and specialty services. The company offers patient-centric programs, such as home visits, telehealth, transition of care, and high risk and complex care management. Cano Health, LLC was founded in 2009 and is based in Miami, Florida.

Please note, on 6/4/21 Jaws Acquisition Corp. (JWS) changed its company name and ticker to Cano Health Inc (CANO). The content of this idea will make reference to the original company name and ticker symbol.

Publicly traded companies mentioned herein: Anthem Inc (ANTM), BlackRock Inc (BLK), Cigna Corp (CI), Humana Inc (HUM), Jaws Acquisition Corp (JWS), Oak Street Health Inc (OSH), UnitedHealth Group Inc (UNH)

Highlights

The presenter is long shares of Jaws Acquisition Corp (JWS), a blank check company that announced in November 2020 its agreement to merge with Cano Health (Cano). The transaction is expected to close in late Q1’21 or early Q2’21, at which point the proforma company will relist under the new ticker symbol CANO. Cano is one of the largest and fastest growing providers of value-based care to Medicare Advantage patients (i.e., the senior citizen market) in the US, a $270B market that is rapidly growing and is expected to reach $500B – $600B in 2025. JWS is led by Barry Sternlicht and notable investors include Fidelity, BlackRock, Third Point, and Maverick Capital. The stock currently trades at ~$15 per share with a ~$7B market cap and a ~$6.8B enterprise value. The presenter is bullish on the market and believes JWS is the best player in the space. The company anticipates generating ~$1.4B of revenues in 2021, and the presenter considers its <5x EV/Revenue valuation as cheap, especially when compared to OSH’s ~12x revenue multiple. He expects meaningful upside as the deal closes and applies a 10x multiple, which implies an equity value of ~$31 per share. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.